ipilimumab,nivolumab,Pembrolizumab
bms,merck
['text,(-texte),(-texti)', 'nivo', 'beat', 'nivolumab', ' ipi ', 'renal,(-adrenal)', 'pembro', 'ipilimumab']
adjuvant ipilimumab/nivolumab not beating placebo in renal cancer is difficult to explain in the context of the pembro data. 6 mnths of therapy and tox of ipi may have played a role. this questions how much is ipi adding here - as a high proportion received 4 cycles #esmo22 
Interested in Urology Cancers, biomarkers and drug development.